The efforts of the final rule aim to simplify the enrollment process for low-income consumers, provide states with more flexibility in offering routine adult dental services and set guidelines to create access to in-network providers.
The U.S. Department of Health and Human Services (HHS) recently introduced the 2025 Notice of Benefit and Payment Parameters final rule, which pushes the Biden-Harris Administration’s ongoing efforts to expand access to quality, affordable healthcare and elevate guidelines for health insurance marketplace (Marketplace) plans nationwide.
CMS joined the initiative and finalized guidelines for issuers and Marketplaces, as well as requirements for various entities assisting Marketplace consumers, affecting programs such as Medicaid, CHIP, and BHP policies, according to CMS.
The efforts of the final rule aim to simplify the enrollment process for low-income consumers, provide states with more flexibility in offering routine adult dental services and set guidelines to create access to in-network providers, per an HHS press release.
In the release, HHS Secretary Xavier Becerra shared that more than 21 million Americans signed up for high-quality, affordable healthcare coverage through the Affordable Care Act Marketplaces in 2024.
“This rule will allow coverage of routine dental benefits for the first time, expand requirements to ensure reliable access to health care providers, and ensure consumers with lower incomes can sign up for coverage when they need it,” Becerra said.
Below are the key advancements of the final rule, per HHS:
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More